PLUR
NASDAQPluri Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$2.47-1.21 (-32.88%)
2026-02-272026-06-02
News · 26 weeks25-25%
2025-12-072026-05-31
Mix990d
- SEC Filings5(56%)
- Other2(22%)
- Offering1(11%)
- Insider1(11%)
Latest news
25 items- PRPluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products ListingTwo regenerative aesthetic and longevity products, with clinically validated ingredients, are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030 HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. ("Cellav"), has completed the development and U.S. cosmetic product listings of two flag
- SECPluri Inc. filed SEC Form 8-K: Other Events8-K - Pluri Inc. (0001158780) (Filer)
- SECSEC Form 10-Q filed by Pluri Inc.10-Q - Pluri Inc. (0001158780) (Filer)
- INSIDERDirector Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Pluri Inc.SCHEDULE 13D/A - Pluri Inc. (0001158780) (Subject)
- SECSEC Form DEFA14A filed by Pluri Inc.DEFA14A - Pluri Inc. (0001158780) (Filer)
- SECSEC Form DEF 14A filed by Pluri Inc.DEF 14A - Pluri Inc. (0001158780) (Filer)
- SECPluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementHAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company's largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to the market price on March 24, 2026. This additional investment follows Mr. Weinstein's prior $2.5 million investment announced in connection with his appointment as Chairman of the Board, and further
- SECPluri Inc. filed SEC Form 8-K: Other Events8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. PatentExpands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion technology Strengthens positioning in China's growing cell therapy market and supports cross-border partnerships HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri", the "Company", "we", "our" or "us") (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces that the China National Intellectual Property Administration (CNIPA) has gra
- SECSEC Form 10-Q filed by Pluri Inc.10-Q - Pluri Inc. (0001158780) (Filer)
- SECPluri Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich BiomaterialsHAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced the completion of the first phase of its program with Resbiomed Technologies OOD ("Resbiomed"), a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri's contract development and manufacturing division, PluriCDMO™. In June 2025, Pluri Biotech Ltd., a wholly owned subsidiary of the Company, and a provider of Contrac
- INSIDERDirector Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- PRPluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing AchievedHAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. ("Remedy Cell"), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. Under the ongoing collaboration Remedy Cell's personnel, along with Pluri's Contract Development and Manufacturing Organization ("CDMO") division (PluriCDMO™), have successfully completed the full imp
- SECPluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional InvestmentWeinstein brings a global track record of transforming companies through value unlocking, and participation in over 20 M&A transactions and more than $5 billion in exits across healthcare, biotechnology, and nutrition.Weinstein's ownership is expected to increase to approximately 30% on an issued and outstanding basis, reflecting his conviction in Pluri's asset base, its valuation potential, and its long term strategy. HAIFA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that Mr. Alejandro Weinstein, one of the C
- INSIDERDirector Manieu Alexandre Weinstein was granted 519 shares, increasing direct ownership by 5% to 10,769 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Ajchenbaum Eitan was granted 668 shares, increasing direct ownership by 6% to 12,353 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERChief Executive Officer Yanay Yaky was granted 6,588 shares, increasing direct ownership by 1% to 497,758 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Levi Rami Avraham was granted 653 shares, increasing direct ownership by 4% to 18,967 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERChief Financial Officer Zalts Liat was granted 3,660 shares, increasing direct ownership by 4% to 92,767 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Shemesh-Rasmussen Maital was granted 699 shares, increasing direct ownership by 4% to 19,144 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Aberman Zami was granted 346 shares, increasing direct ownership by 0.24% to 144,212 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
PLUR FAQ
4 questionsWhere does PLUR stock trade?
Pluri Inc. (PLUR) is listed on NASDAQ.What sector and industry is PLUR in?
Pluri Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to PLUR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare PLUR side-by-side with any of them on Quantisnow.How can I track PLUR on Quantisnow?
Quantisnow aggregates Pluri Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PLUR to receive live email and push alerts on every new disclosure.